

Terry J Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5401213/publications.pdf>

Version: 2024-02-01

251
papers

14,623
citations

15504

65
h-index

25787

108
g-index

280
all docs

280
docs citations

280
times ranked

7638
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 update on thyroid-associated ophthalmopathy. Journal of Endocrinological Investigation, 2022, 45, 235-259.	3.3	44
2	Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders. Journal of Neurology, 2022, 269, 1786-1801.	3.6	8
3	Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment. Ophthalmology, 2022, 129, 438-449.	5.2	64
4	It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, S1-S12.	3.6	17
5	Does Anatomic Region-Specific Gene Expression Underlie Thyroid Eye Disease?. Ophthalmic Plastic and Reconstructive Surgery, 2022, Publish Ahead of Print, .	0.8	0
6	Longitudinal Retinal Changes in <sc>MOGAD</sc>. Annals of Neurology, 2022, 92, 476-485.	5.3	20
7	Teprotumumab Divergently Alters Fibrocyte Gene Expression: Implications for Thyroid-associated Ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e4037-e4047.	3.6	2
8	Teprotumumab for Optic Neuropathy in Thyroid Eye Disease. JAMA Ophthalmology, 2021, 139, 244.	2.5	29
9	Slit2 Regulates Hyaluronan & Cytokine Synthesis in Fibrocytes: Potential Relevance to Thyroid-Associated Ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e20-e33.	3.6	16
10	Teprotumumab in Clinical Practice: Recommendations and Considerations From the OPTIC Trial Investigators. Journal of Neuro-Ophthalmology, 2021, 41, 461-468.	0.8	19
11	Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy. Cells, 2021, 10, 383.	4.1	10
12	Insulin-Like Growth Factor Pathway and the Thyroid. Frontiers in Endocrinology, 2021, 12, 653627.	3.5	29
13	Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes and Endocrinology, 2021, 9, 360-372.	11.4	91
14	Comment on the 2021 EUGOGO Clinical Practice Guidelines for the Medical Management of Gravesâ€™ Orbitopathy. European Journal of Endocrinology, 2021, 185, L13-L14.	3.7	9
15	Efficacy and Safety of Teprotumumab in Thyroid Eye Disease. Therapeutics and Clinical Risk Management, 2021, Volume 17, 1219-1230.	2.0	10
16	Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	20
17	Teprotumumab Treatment for Thyroid-Associated Ophthalmopathy. European Thyroid Journal, 2020, 9, 31-39.	2.4	5
18	Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101383.	4.7	10

#	ARTICLE	IF	CITATIONS
19	High-throughput investigation of molecular and cellular biomarkers in NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	20
20	Slit2 May Underlie Divergent Induction by Thyrotropin of IL-23 and IL-12 in Human Fibrocytes. <i>Journal of Immunology</i> , 2020, 204, 1724-1735.	0.8	17
21	Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy. <i>Frontiers in Endocrinology</i> , 2020, 11, 610337.	3.5	4
22	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). <i>BMJ Open</i> , 2020, 10, e035397.	1.9	10
23	Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 645-649.	4.1	13
24	Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor- α Receptor Inhibition. <i>Journal of Neuro-Ophthalmology</i> , 2020, 40, 74-83.	0.8	5
25	Teprotumumab for the Treatment of Active Thyroid Eye Disease. <i>New England Journal of Medicine</i> , 2020, 382, 341-352.	27.0	375
26	Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy. <i>Annual Review of Pharmacology and Toxicology</i> , 2019, 59, 129-148.	9.4	25
27	Neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e580.	6.0	92
28	Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e583.	6.0	33
29	Insulin-like Growth Factor- α Receptor and Thyroid-Associated Ophthalmopathy. <i>Endocrine Reviews</i> , 2019, 40, 236-267.	20.1	117
30	Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study. <i>Journal of Neuroinflammation</i> , 2019, 16, 59.	7.2	39
31	Response to Letter to the Editor: "Elevated Serum Tetrac in Graves Disease: Potential Pathogenic Role in Thyroid-Associated Ophthalmopathy", <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1077-1078.	3.6	0
32	HIF2 α -LOX Pathway Promotes Fibrotic Tissue Remodeling in Thyroid-Associated Orbitopathy. <i>Endocrinology</i> , 2019, 160, 20-35.	2.8	65
33	Potential Roles of CD34+ Fibrocytes Masquerading as Orbital Fibroblasts in Thyroid-Associated Ophthalmopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 581-594.	3.6	27
34	Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?. <i>European Journal of Endocrinology</i> , 2019, 181, D27-D43.	3.7	19
35	40 YEARS OF IGF1: IGF1 receptor and thyroid-associated ophthalmopathy. <i>Journal of Molecular Endocrinology</i> , 2018, 61, T29-T43.	2.5	50
36	Magnetic resonance imaging findings at the first episode of acute optic neuritis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 30-36.	2.0	23

#	ARTICLE	IF	CITATIONS
37	New advances in understanding thyroid-associated ophthalmopathy and the potential role for insulin-like growth factor-I receptor. F1000Research, 2018, 7, 134.	1.6	15
38	Is there potential for the approval of monoclonal antibodies to treat thyroid-associated ophthalmopathy?. Expert Opinion on Orphan Drugs, 2018, 6, 593-595.	0.8	7
39	Slit2 Modulates the Inflammatory Phenotype of Orbit-Infiltrating Fibrocytes in Gravesâ€™ Disease. Journal of Immunology, 2018, 200, 3942-3949.	0.8	31
40	CD34â€™ Orbital Fibroblasts From Patients With Thyroid-Associated Ophthalmopathy Modulate TNF-Î± Expression in CD34+ Fibroblasts and Fibrocytes. , 2018, 59, 2615.		18
41	Gravesâ€™ Ophthalmopathy. Endocrinology, 2018, , 451-488.	0.1	0
42	TSHR as a therapeutic target in Gravesâ€™ disease. Expert Opinion on Therapeutic Targets, 2017, 21, 427-432.	3.4	27
43	Gravesâ€™ Disease. New England Journal of Medicine, 2017, 376, 184-185.	27.0	42
44	Teprotumumab for Thyroid-Associated Ophthalmopathy. New England Journal of Medicine, 2017, 376, 1748-1761.	27.0	480
45	A population-based prospective study of optic neuritis. Multiple Sclerosis Journal, 2017, 23, 1893-1901.	3.0	81
46	Response to Krieger et al. re: â€œTSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesisâ€•(Thyroid 2017;27:746â€“747). Thyroid, 2017, 27, 1458-1459.	4.5	10
47	De novo triiodothyronine formation from thyrocytes activated by thyroid-stimulating hormone. Journal of Biological Chemistry, 2017, 292, 15434-15444.	3.4	27
48	Elevated Serum Tetrac in Graves Disease: Potential Pathogenic Role in Thyroid-Associated Ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 776-785.	3.6	11
49	CD40 Expression in Fibrocytes Is Induced by TSH: Potential Synergistic Immune Activation. PLoS ONE, 2016, 11, e0162994.	2.5	8
50	Rationale for therapeutic targeting insulin-like growth factor-1 receptor and bone marrow-derived fibrocytes in thyroid-associated ophthalmopathy. Expert Review of Ophthalmology, 2016, 11, 77-79.	0.6	5
51	Restoring immune tolerance in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e277.	6.0	39
52	Restoring immune tolerance in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e276.	6.0	35
53	Intersection of Chemokine and TSH Receptor Pathways in Human Fibrocytes: Emergence of CXCL-12/CXCR4 Cross Talk Potentially Relevant to Thyroid-Associated Ophthalmopathy. Endocrinology, 2016, 157, 3779-3787.	2.8	12
54	Thyrotropin and CD40L Stimulate Interleukin-12 Expression in Fibrocytes: Implications for Pathogenesis of Thyroid-Associated Ophthalmopathy. Thyroid, 2016, 26, 1768-1777.	4.5	17

#	ARTICLE	IF	CITATIONS
55	Aquaporin-4 IgG autoimmune syndrome and immunoreactivity associated with thyroid cancer. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e252.	6.0	11
56	Gravesâ€™ Disease. <i>New England Journal of Medicine</i> , 2016, 375, 1552-1565.	27.0	847
57	Update on thyroid-associated Ophthalmopathy with a special emphasis on the ocular surface. <i>Clinical Diabetes and Endocrinology</i> , 2016, 2, 19.	2.7	23
58	Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy. <i>Frontiers in Endocrinology</i> , 2016, 7, 167.	3.5	31
59	Gravesâ€™ Ophthalmopathy. <i>Endocrinology</i> , 2016, , 1-39.	0.1	0
60	Altered balance between self-reactive T helper (Th)17 cells and Th10 cells and between full-length forkhead box protein 3 (FoxP3) and FoxP3 splice variants in Hashimoto's thyroiditis. <i>Clinical and Experimental Immunology</i> , 2015, 180, 58-69.	2.6	40
61	Disrupted TSH Receptor Expression in Female Mouse Lung Fibroblasts Alters Subcellular IGF-1 Receptor Distribution. <i>Endocrinology</i> , 2015, 156, 4731-4740.	2.8	6
62	Characterization of Regulatory B Cells in Gravesâ€™ Disease and Hashimotoâ€™s Thyroiditis. <i>PLoS ONE</i> , 2015, 10, e0127949.	2.5	41
63	Risk Factors for Developing Thyroid-Associated Ophthalmopathy Among Individuals With Graves Disease. <i>JAMA Ophthalmology</i> , 2015, 133, 290.	2.5	120
64	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015, 72, 815.	9.0	59
65	TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy. <i>Nature Reviews Endocrinology</i> , 2015, 11, 171-181.	9.6	78
66	Challenges and opportunities in designing clinical trials for neuromyelitis optica. <i>Neurology</i> , 2015, 84, 1805-1815.	1.1	39
67	Pentraxin-3 Is a TSH-Inducible Protein in Human Fibrocytes and Orbital Fibroblasts. <i>Endocrinology</i> , 2015, 156, 4336-4344.	2.8	20
68	B lymphocytes in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e104.	6.0	132
69	Update on biomarkers in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e134.	6.0	104
70	Emerging Role of Fibrocytes in the Pathogenesis of Thyroid Eye Disease. , 2015, , 23-32.		0
71	Rituximab (Rituxan) Therapy for Severe Thyroid-Associated Ophthalmopathy Diminishes IGF-1R+ T Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1294-E1299.	3.6	19
72	Teprotumumab, an IGF-1R Blocking Monoclonal Antibody Inhibits TSH and IGF-1 Action in Fibrocytes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1635-E1640.	3.6	119

#	ARTICLE	IF	CITATIONS
73	PI3K/AKT Pathway Mediates Induction of IL-1RA by TSH in Fibrocytes: Modulation by PTEN. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3363-3372.	3.6	28
74	Cytokines as villains and potential therapeutic targets in thyroid-associated ophthalmopathy: from bench to bedside. Expert Review of Ophthalmology, 2014, 9, 227-234.	0.6	22
75	Regulation of IL-1 Receptor Antagonist by TSH in Fibrocytes and Orbital Fibroblasts. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E625-E633.	3.6	28
76	Advances in Understanding Autoimmune Pituitary Disease: Standardized Methods for Autoantibody Detection. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1589-1592.	3.6	1
77	Expression of Thyrotropin Receptor, Thyroglobulin, Sodium-Iodide Symporter, and Thyroperoxidase by Fibrocytes Depends on AIRE. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1236-E1244.	3.6	52
78	Current Concepts in the Molecular Pathogenesis of Thyroid-Associated Ophthalmopathy. , 2014, 55, 1735.		181
79	Human Fibrocytes Express Multiple Antigens Associated With Autoimmune Endocrine Diseases. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E796-E803.	3.6	18
80	Is IGF-I Receptor a Target for Autoantibody Generation in Graves' Disease?. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 515-518.	3.6	30
81	Divergent Expression of IL-1 Receptor Antagonists in CD34+ Fibrocytes and Orbital Fibroblasts in Thyroid-associated Ophthalmopathy: Contribution of Fibrocytes to Orbital Inflammation. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2783-2790.	3.6	24
82	Thyrotropin Regulates IL-6 Expression in CD34+ Fibrocytes: Clear Delineation of Its cAMP-Independent Actions. PLoS ONE, 2013, 8, e75100.	2.5	50
83	Histopathology of Brow Fat in Thyroid-Associated Orbitopathy. Ophthalmic Plastic and Reconstructive Surgery, 2012, 28, 27-29.	0.8	24
84	Human fibrocytes coexpress thyroglobulin and thyrotropin receptor. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7427-7432.	7.1	77
85	Increased Expression of TSH Receptor by Fibrocytes in Thyroid-Associated Ophthalmopathy Leads to Chemokine Production. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E740-E746.	3.6	72
86	Treating the thyroid in the presence of Graves's ophthalmopathy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 313-324.	4.7	30
87	Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves's orbitopathy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 291-302.	4.7	97
88	Integrative Continuum: Accelerating Therapeutic Advances in Rare Autoimmune Diseases. Annual Review of Pharmacology and Toxicology, 2012, 52, 523-547.	9.4	8
89	Nuclear Targeting of IGF-1 Receptor in Orbital Fibroblasts from Graves' Disease: Apparent Role of ADAM17. PLoS ONE, 2012, 7, e34173.	2.5	21
90	Interleukin-6 Production in CD40-Engaged Fibrocytes in Thyroid-Associated Ophthalmopathy: Involvement of Akt and NF- κ B. , 2012, 53, 7746.		56

#	ARTICLE	IF	CITATIONS
91	Thyroid Eye Disease: Towards an Evidence Base for Treatment in the 21st Century. Current Neurology and Neuroscience Reports, 2012, 12, 318-324.	4.2	36
92	Pathogenesis and Medical Management of Thyroid Eye Disease. , 2012, , 1213-1223.		0
93	Targeted biological therapies for Gravesâ€™ disease and thyroidâ€“associated ophthalmopathy. Focus on Bâ€cell depletion with Rituximab. Clinical Endocrinology, 2011, 74, 1-8.	2.4	46
94	Fibroblasts Expressing the Thyrotropin Receptor Overarch Thyroid and Orbit in Graves' Disease. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3827-3837.	3.6	48
95	Does selenium supplementation improve Graves ophthalmopathy?. Nature Reviews Endocrinology, 2011, 7, 505-506.	9.6	6
96	Other Potential Therapeutic Targets in Thyroid Orbitopathy. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2011, 11, 112-117.	0.5	0
97	Divergent Sp1 Protein Levels May Underlie Differential Expression of UDP-Glucose Dehydrogenase by Fibroblasts. Journal of Biological Chemistry, 2011, 286, 24487-24499.	3.4	26
98	Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA. Journal of Endocrinology, 2011, 210, 369-377.	2.6	63
99	The Putative Role of Fibrocytes in the Pathogenesis of Gravesâ€™ Disease. , 2011, , 271-284.		0
100	Potential role for bone marrow-derived fibrocytes in the orbital fibroblast heterogeneity associated with thyroid-associated ophthalmopathy. Clinical and Experimental Immunology, 2010, 162, 24-31.	2.6	22
101	PGE2 Induces IL-6 in Orbital Fibroblasts through EP2 Receptors and Increased Gene Promoter Activity: Implications to Thyroid-Associated Ophthalmopathy. PLoS ONE, 2010, 5, e15296.	2.5	36
102	Transforming growth factor Î²₁ and laminin-111 cooperate in the induction of interleukin-16 expression in synovial fibroblasts from patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 270-275.	0.9	18
103	Insulin-Like Growth Factor-I Regulation of Immune Function: A Potential Therapeutic Target in Autoimmune Diseases?. Pharmacological Reviews, 2010, 62, 199-236.	16.0	226
104	Increased Generation of Fibrocytes in Thyroid-Associated Ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 430-438.	3.6	199
105	Pathogenesis of Gravesâ€™ orbitopathy: A 2010 update. Journal of Endocrinological Investigation, 2010, 33, 414-421.	3.3	81
106	Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy. Ophthalmology, 2010, 117, 133-139.e2.	5.2	159
107	Immunopathogenesis of Thyroid Eye Disease: Emerging Paradigms. Survey of Ophthalmology, 2010, 55, 215-226.	4.0	97
108	Orbital Fibroblasts from Patients with Thyroid-Associated Ophthalmopathy Overexpress CD40: CD154 Hyperinduces IL-6, IL-8, and MCP-1. , 2009, 50, 2262.		121

#	ARTICLE	IF	CITATIONS
109	Divergent Frequencies of IGF-I Receptor-Expressing Blood Lymphocytes in Monozygotic Twin Pairs Discordant for Gravesâ€™ Disease: Evidence for a Phenotypic Signature Ascribable to Nongenetic Factors. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1797-1802.	3.6	12
110	Characterization of the anaemia associated with Gravesâ€™ disease. Clinical Endocrinology, 2009, 70, 781-787.	2.4	34
111	Development of Criteria for Evaluating Clinical Response in Thyroid Eye Disease Using a Modified Delphi Technique. JAMA Ophthalmology, 2009, 127, 1155.	2.4	30
112	Regulation of Lymphocyte Function by PPAR<math xmlns:mml="http://www.w3.org/1998/Math/MathML">γ</math>: Relevance to Thyroid Eye Disease-Related Inflammation. PPAR Research, 2008, 2008, 1-12.	2.4	27
113	Cytokines, Graves' Disease, and Thyroid-Associated Ophthalmopathy. Thyroid, 2008, 18, 953-958.	4.5	108
114	Evidence for an Association between Thyroid-Stimulating Hormone and Insulin-Like Growth Factor 1 Receptors: A Tale of Two Antigens Implicated in Gravesâ€™ Disease. Journal of Immunology, 2008, 181, 4397-4405.	0.8	272
115	B Cells from Patients with Gravesâ€™ Disease Aberrantly Express the IGF-1 Receptor: Implications for Disease Pathogenesis. Journal of Immunology, 2008, 181, 5768-5774.	0.8	104
116	Immune Mechanisms in Thyroid Eye Disease. Thyroid, 2008, 18, 959-965.	4.5	140
117	Unique Attributes of Orbital Fibroblasts and Global Alterations in IGF-1 Receptor Signaling Could Explain Thyroid-Associated Ophthalmopathy. Thyroid, 2008, 18, 983-988.	4.5	93
118	Biologic Therapeutics in Thyroid-Associated Ophthalmopathy: Translating Disease Mechanism into Therapy. Thyroid, 2008, 18, 967-971.	4.5	48
119	Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy. Current Opinion in Endocrinology, Diabetes and Obesity, 2008, 15, 446-452.	2.3	29
120	Pathophysiology of Graves' Orbitopathy. , 2008, , 2913-2926.		3
121	TGFâ€³ enhances the lamininâ€³-induced production of ILâ€³ in RA synovial fibroblasts by elevation of betaâ€³ integrin expression. FASEB Journal, 2008, 22, 664.13.	0.5	0
122	Jak2 Dampens the Induction by IL-1Î² of Prostaglandin Endoperoxide H Synthase 2 Expression in Human Orbital Fibroblasts: Evidence for Divergent Influence on the Prostaglandin E2 Biosynthetic Pathway. Journal of Immunology, 2007, 179, 7147-7156.	0.8	6
123	B Cell Depletion in Gravesâ€™ Disease: The Right Answer to the Wrong Question?. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1620-1622.	3.6	11
124	Hyaluronan Accumulation in Thyroid Tissue: Evidence for Contributions from Epithelial Cells and Fibroblasts. Endocrinology, 2007, 148, 54-62.	2.8	36
125	Aberrant Expression of the Insulin-Like Growth Factor-1 Receptor by T Cells from Patients with Gravesâ€™ Disease May Carry Functional Consequences for Disease Pathogenesis. Journal of Immunology, 2007, 178, 3281-3287.	0.8	129
126	Is a common therapy for autoimmune disease possible?. Future Rheumatology, 2007, 2, 333-335.	0.2	0

#	ARTICLE	IF	CITATIONS
127	Circulating mononuclear cells from euthyroid patients with thyroid-associated ophthalmopathy exhibit characteristic phenotypes. Clinical and Experimental Immunology, 2007, 148, 64-71.	2.6	20
128	Immunoglobulin G from Patients with Gravesâ€™ Disease Induces Interleukin-16 and RANTES Expression in Cultured Human Thyrocytes: A Putative Mechanism for T-Cell Infiltration of the Thyroid in Autoimmune Disease. Endocrinology, 2006, 147, 1941-1949.	2.8	49
129	Molecular Pathology of Müllerâ€™s Muscle in Gravesâ€™ Ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1159-1167.	3.6	33
130	T Helper Type 1 and Type 2 Cytokines Exert Divergent Influence on the Induction of Prostaglandin E2 and Hyaluronan Synthesis by Interleukin-1Î² in Orbital Fibroblasts: Implications for the Pathogenesis of Thyroid-Associated Ophthalmopathy. Endocrinology, 2006, 147, 13-19.	2.8	89
131	Interleukin-6 release from human abdominal adipose cells is regulated by thyroid-stimulating hormone: effect of adipocyte differentiation and anatomic depot. American Journal of Physiology - Endocrinology and Metabolism, 2006, 290, E1140-E1144.	3.5	55
132	Interleukin-4 Induces 15-Lipoxygenase-1 Expression in Human Orbital Fibroblasts from Patients with Graves Disease. Journal of Biological Chemistry, 2006, 281, 18296-18306.	3.4	38
133	Monoclonal Pathogenic Antibodies to the Thyroid-Stimulating Hormone Receptor in Gravesâ€™ Disease with Potent Thyroid-Stimulating Activity but Differential Blocking Activity Activate Multiple Signaling Pathways. Journal of Immunology, 2006, 176, 5084-5092.	0.8	61
134	More Than Structural Cells, Fibroblasts Create and Orchestrate the Tumor Microenvironment. Immunological Investigations, 2006, 35, 297-325.	2.0	99
135	Functional Assessment of Fibroblast Heterogeneity by the Cell-Surface Glycoprotein Thy-1. , 2006, , 32-39.		1
136	IL-1 Induces Lower sIL-1ra and Higher icIL-1ra IL-1ra Protein Expression in Orbital vs. Dermal Fibroblasts. FASEB Journal, 2006, 20, A640.	0.5	0
137	Isolation and Phenotypic Characterization of Lung Fibroblasts. , 2005, 117, 115-127.		63
138	Insights into the role of fibroblasts in human autoimmune diseases. Clinical and Experimental Immunology, 2005, 141, 388-397.	2.6	88
139	Rosiglitazone-Induced Proptosis. JAMA Ophthalmology, 2005, 123, 119.	2.4	33
140	Induction by IL-1Î² of Tissue Inhibitor of Metalloproteinase-1 in Human Orbital Fibroblasts: Modulation of Gene Promoter Activity by IL-4 and IFN-Î³. Journal of Immunology, 2005, 174, 3072-3079.	0.8	49
141	IL-1Î² Induces IL-6 Expression in Human Orbital Fibroblasts: Identification of an Anatomic-Site Specific Phenotypic Attribute Relevant to Thyroid-Associated Ophthalmopathy. Journal of Immunology, 2005, 175, 1310-1319.	0.8	115
142	Immunoglobulins from Patients with Gravesâ€™ Disease Induce Hyaluronan Synthesis in Their Orbital Fibroblasts through the Self-Antigen, Insulin-Like Growth Factor-I Receptor. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5076-5080.	3.6	222
143	Synovial Fibroblasts from Patients with Rheumatoid Arthritis, Like Fibroblasts from Gravesâ€™ Disease, Express High Levels of IL-16 When Treated with Igs against Insulin-Like Growth Factor-1 Receptor. Journal of Immunology, 2004, 173, 3564-3569.	0.8	67
144	A novel ELISpot method for adherent cells. Journal of Immunological Methods, 2004, 291, 63-70.	1.4	16

#	ARTICLE	IF	CITATIONS
145	Novel aspects of orbital fibroblast pathology. Journal of Endocrinological Investigation, 2004, 27, 246-253.	3.3	54
146	Thy-1 Expression in Human Fibroblast Subsets Defines Myofibroblastic or Lipofibroblastic Phenotypes. American Journal of Pathology, 2003, 163, 1291-1300.	3.8	237
147	Current Perspective on the Pathogenesis of Graves's™ Disease and Ophthalmopathy. Endocrine Reviews, 2003, 24, 802-835.	20.1	415
148	Immunoglobulin Activation of T Cell Chemoattractant Expression in Fibroblasts from Patients with Graves's™ Disease Is Mediated Through the Insulin-Like Growth Factor I Receptor Pathway. Journal of Immunology, 2003, 170, 6348-6354.	0.8	246
149	Cytokine-Induced Lymphocyte Chemoattraction from Cultured Human Thyrocytes: Evidence for Interleukin-16 and Regulated upon Activation, Normal T Cell Expressed, and Secreted Expression. Endocrinology, 2003, 144, 2856-2864.	2.8	17
150	The Putative Role of Fibroblasts in the Pathogenesis of Graves' Disease: Evidence for the Involvement of the Insulin-like Growth Factor-1 Receptor in Fibroblast Activation. Autoimmunity, 2003, 36, 409-415.	2.6	61
151	Robust induction of PGHS-2 by IL-1 in orbital fibroblasts results from low levels of IL-1 receptor antagonist expression. American Journal of Physiology - Cell Physiology, 2003, 284, C1429-C1437.	4.6	22
152	Unique properties of orbital connective tissue underlie its involvement in Graves' disease. Minerva Endocrinologica, 2003, 28, 213-22.	1.8	8
153	Orbital Fibroblasts Exhibit a Novel Pattern of Responses to Proinflammatory Cytokines: Potential Basis for the Pathogenesis of Thyroid-Associated Ophthalmopathy. Thyroid, 2002, 12, 197-203.	4.5	67
154	Igs from Patients with Graves's™ Disease Induce the Expression of T Cell Chemoattractants in Their Fibroblasts. Journal of Immunology, 2002, 168, 942-950.	0.8	153
155	Insights Into the Pathogenesis of Thyroid-Associated Orbitopathy. JAMA Ophthalmology, 2002, 120, 380.	2.4	146
156	Up-regulation of Prostaglandin E2 Synthesis by Interleukin-1 β in Human Orbital Fibroblasts Involves Coordinate Induction of Prostaglandin-Endoperoxide H Synthase-2 and Glutathione-dependent Prostaglandin E2 Synthase Expression. Journal of Biological Chemistry, 2002, 277, 16355-16364.	3.4	142
157	Orbital Fibroblast Heterogeneity May Determine the Clinical Presentation of Thyroid-Associated Ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 385-392.	3.6	190
158	Cytoplasmic Prostaglandin E2 Synthase Is Dominantly Expressed in Cultured KAT-50 Thyrocytes, Cells That Express Constitutive Prostaglandin-endoperoxide H Synthase-2. Journal of Biological Chemistry, 2002, 277, 36897-36903.	3.4	14
159	Fibroblast biology in thyroid diseases. Current Opinion in Endocrinology, Diabetes and Obesity, 2002, 9, 393-400.	0.6	16
160	Fibroblast subsets in the human orbit: Thy-1+ and Thy-1- subpopulations exhibit distinct phenotypes. European Journal of Immunology, 2002, 32, 477-485.	2.9	138
161	Orbital Fibroblast Heterogeneity May Determine the Clinical Presentation of Thyroid-Associated Ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 385-392.	3.6	48
162	Prostaglandin endoperoxide H synthase expression in human thyroid epithelial cells. American Journal of Physiology - Cell Physiology, 2001, 280, C701-C708.	4.6	19

#	ARTICLE	IF	CITATIONS
163	Advanced breast biopsy instrumentation (ABBI) and management of nonpalpable breast abnormalities: a community hospital experience. Breast, 2001, 10, 421-426.	2.2	3
164	Fibroblasts as Sentinel Cells. Chest, 2001, 120, S53-S55.	0.8	58
165	Participation of Orbital Fibroblasts in the Inflammation of Gravesâ€™ Ophthalmopathy. Growth Hormone, 2001, , 83-98.	0.2	1
166	Functional TSH receptor in human abdominal preadipocytes and orbital fibroblasts. American Journal of Physiology - Cell Physiology, 2000, 279, C335-C340.	4.6	122
167	Cultured Human Fibroblasts Express Constitutive IL-16 mRNA: Cytokine Induction of Active IL-16 Protein Synthesis Through a Caspase-3-Dependent Mechanism. Journal of Immunology, 2000, 164, 3806-3814.	0.8	96
168	Peroxisome Proliferator Activator Receptor-Î³ Agonists and 15-Deoxy-Î³ ^{12,14} PGJ2 Induce Apoptosis in Normal and Malignant B-Lineage Cells. Journal of Immunology, 2000, 165, 6941-6948.	0.8	148
169	Gravesâ€™ Dermopathy. Growth Hormone, 2000, , 289-300.	0.2	0
170	Leukoregulin upregulation of prostaglandin endoperoxide H synthase-2 expression in human orbital fibroblasts. American Journal of Physiology - Cell Physiology, 1999, 277, C1075-C1085.	4.6	47
171	Expression of Hyaluronan Synthase Messenger Ribonucleic Acids and Their Induction by Interleukin-1Î² in Human Orbital Fibroblasts: Potential Insight into the Molecular Pathogenesis of Thyroid-Associated Ophthalmopathy1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4079-4084.	3.6	89
172	The putative role of prostaglandin endoperoxide H synthase-2 in the pathogenesis of thyroid-associated orbitopathy. Experimental and Clinical Endocrinology and Diabetes, 1999, 107, S160-S163.	1.2	14
173	HMC-1 Mast Cells Activate Human Orbital Fibroblasts in Coculture: Evidence for Up-Regulation of Prostaglandin E2 and Hyaluronan Synthesis*. Endocrinology, 1999, 140, 3518-3525.	2.8	50
174	Prostaglandin-endoperoxide H Synthase-2 Expression in Human Thyroid Epithelium. Journal of Biological Chemistry, 1999, 274, 15622-15632.	3.4	30
175	CD40 Expression in Human Thyroid Tissue: Evidence for Involvement of Multiple Cell Types in Autoimmune and Neoplastic Diseases. Thyroid, 1999, 9, 749-755.	4.5	65
176	The Effect of Cigarette Smoke Constituents on the Expression of HLA-DR in Orbital Fibroblasts Derived from Patients with Graves Ophthalmopathy. Ophthalmic Plastic and Reconstructive Surgery, 1999, 15, 260-271.	0.8	44
177	HMC-1 Mast Cells Activate Human Orbital Fibroblasts in Coculture: Evidence for Up-Regulation of Prostaglandin E2 and Hyaluronan Synthesis. Endocrinology, 1999, 140, 3518-3525.	2.8	16
178	Assessment of Rapid Morphological Changes Associated with Elevated cAMP Levels in Human Orbital Fibroblasts. Experimental Cell Research, 1998, 245, 360-367.	2.6	43
179	CYCLOOXYGENASES AS THE PRINCIPAL TARGETS FOR THE ACTIONS OF NSAIDs. Rheumatic Disease Clinics of North America, 1998, 24, 501-523.	1.9	38
180	Activation of Human Orbital Fibroblasts through CD40 Engagement Results in a Dramatic Induction of Hyaluronan Synthesis and Prostaglandin Endoperoxide H Synthase-2 Expression. Journal of Biological Chemistry, 1998, 273, 29615-29625.	3.4	175

#	ARTICLE	IF	CITATIONS
181	Molecular Cloning and Characterization of the Human and Mouse UDP-Glucose Dehydrogenase Genes. Journal of Biological Chemistry, 1998, 273, 25117-25124.	3.4	133
182	Leukoregulin induction of protein expression in human orbital fibroblasts: Evidence for anatomical site-restricted cytokine-target cell interactions. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 8904-8909.	7.1	65
183	Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. American Journal of Physiology - Cell Physiology, 1998, 274, C707-C714.	4.6	140
184	Cytokine-mediated PGE ₂ expression in human colonic fibroblasts. American Journal of Physiology - Cell Physiology, 1998, 275, C988-C994.	4.6	54
185	CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts. Journal of Immunology, 1998, 160, 1053-7.	0.8	98
186	Human Thyroid Fibroblasts Exhibit a Distinctive Phenotype in Culture: Characteristic Ganglioside Profile and Functional CD40 Expression*. Endocrinology, 1997, 138, 5576-5588.	2.8	36
187	Human Thyroid Fibroblasts Exhibit a Distinctive Phenotype in Culture: Characteristic Ganglioside Profile and Functional CD40 Expression. Endocrinology, 1997, 138, 5576-5588.	2.8	14
188	Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. American Journal of Pathology, 1997, 151, 317-22.	3.8	415
189	n-Butyrate induces plasminogen activator inhibitor type 1 messenger RNA in cultured Hep G2 cells. Hepatology, 1996, 23, 866-871.	7.3	22
190	Leukoregulin Induction of Prostaglandin-Endoperoxide H Synthase-2 in Human Orbital Fibroblasts. Journal of Biological Chemistry, 1996, 271, 22718-22728.	3.4	94
191	The putative role of cytokine-orbital fibroblast interactions in the pathogenesis of thyroid-associated ophthalmopathy. Orbit, 1996, 15, 137-146.	0.8	1
192	Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 3428-3431.	3.6	141
193	n-Butyrate induces plasminogen activator inhibitor type 1 messenger RNA in cultured Hep G2 cells. Hepatology, 1996, 23, 866-871.	7.3	6
194	Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 3428-3431.	3.6	98
195	Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts. An in vitro model for connective tissue inflammation. Journal of Biological Chemistry, 1996, 271, 22718-28.	3.4	26
196	Leukoregulin induces plasminogen activator inhibitor type 1 in human orbital fibroblasts. American Journal of Physiology - Cell Physiology, 1995, 269, C359-C366.	4.6	30
197	Leukoregulin is a potent inducer of hyaluronan synthesis in cultured human orbital fibroblasts. American Journal of Physiology - Cell Physiology, 1995, 268, C382-C388.	4.6	108
198	Human orbital fibroblasts in culture express ganglioside profiles distinct from those in dermal fibroblasts.. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 2668-2674.	3.6	19

#	ARTICLE	IF	CITATIONS
199	Prostaglandin E2 alters human orbital fibroblast shape through a mechanism involving the generation of cyclic adenosine monophosphate.. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 3553-3560.	3.6	20
200	Evidence for cellular heterogeneity in primary cultures of human orbital fibroblasts.. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 2620-2625.	3.6	100
201	Evidence for cellular heterogeneity in primary cultures of human orbital fibroblasts. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 2620-2625.	3.6	82
202	Transforming growth factor-beta induces plasminogen activator inhibitor type-1 in cultured human orbital fibroblasts. Investigative Ophthalmology and Visual Science, 1995, 36, 1411-9.	3.3	23
203	Ultrastructure of cultured human orbital fibroblasts. Cell and Tissue Research, 1994, 278, 629-631.	2.9	15
204	Retinoic acid inhibition of thyroxine binding to human transthyretin. Biochimica Et Biophysica Acta - General Subjects, 1994, 1199, 76-80.	2.4	31
205	Prostaglandin E2 elicits a morphological change in cultured orbital fibroblasts from patients with Graves ophthalmopathy.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 5094-5098.	7.1	67
206	Interferon Gamma Regulation of De Novo Protein Synthesis in Human Dermal Fibroblasts in Culture Is Anatomic Site Dependent. Journal of Investigative Dermatology, 1993, 100, 288-292.	0.7	31
207	Pleotrophic action of interferon gamma in human orbital fibroblasts. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1993, 1181, 23-30.	3.8	20
208	Bidimensional gel electrophoretic analysis of protein synthesis and response to interferon- γ in cultured human dermal fibroblasts. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1993, 1181, 300-306.	3.8	14
209	Human orbital fibroblasts in culture bind and respond to endothelin. American Journal of Physiology - Cell Physiology, 1993, 265, C138-C142.	4.6	28
210	Stereochemical requirements for the modulation by retinoic acid of thyroid hormone activation of Ca ²⁺ -ATPase and binding at the human erythrocyte membrane. Biochemical Journal, 1992, 284, 583-587.	3.7	19
211	Interferon-gamma is an inducer of plasminogen activator inhibitor type 1 in human orbital fibroblasts. American Journal of Physiology - Cell Physiology, 1992, 263, C24-C29.	4.6	75
212	Regulation by glucocorticoids of interferon gamma-induced HLA-DR antigen expression in cultured human orbital fibroblasts. Clinical Endocrinology, 1992, 37, 59-63.	2.4	19
213	Induction of heme oxygenase mRNA by cobalt protoporphyrin in rat liver. Biochimica Et Biophysica Acta - General Subjects, 1991, 1073, 221-224.	2.4	8
214	Retinoic acid can enhance the stimulation by thyroid hormone of heme oxygenase activity in the liver of thyroidectomized rats. Biochimica Et Biophysica Acta - General Subjects, 1991, 1075, 119-122.	2.4	12
215	Sex-dependent inhibition by retinoic acid of thyroid-hormone action on rabbit reticulocyte Ca ²⁺ -ATPase activity. Biochemical Journal, 1991, 273, 489-492.	3.7	0
216	Structure-activity relationships of retinoids as inhibitors of calmodulin-dependent human erythrocyte Ca ²⁺ -ATPase activity and calmodulin binding to membranes. Biochemical Journal, 1991, 277, 603-606.	3.7	6

#	ARTICLE	IF	CITATIONS
217	Isolation and characterization of a novel liver-derived immunoinhibitory factor. <i>Hepatology</i> , 1991, 14, 888-894.	7.3	7
218	Increased Induction of HLA-DR by Interferon- γ in Cultured Fibroblasts Derived from Patients with Graves' Ophthalmopathy and Pretibial Dermopathy*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 73, 307-313.	3.6	99
219	STIMULATION OF GLYCOSAMINOGLYCAN ACCUMULATION BY INTERFERON GAMMA IN CULTURED HUMAN RETROOCULAR FIBROBLASTS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 72, 1169-1171.	3.6	134
220	Phylogenetic distribution and function of arylalkylamine N-acetyltransferase. <i>BioEssays</i> , 1990, 12, 30-33.	2.5	28
221	Retinoic Acid Inhibition of Hyaluronate Synthesis in Cultured Human Skin Fibroblasts*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 70, 655-660.	3.6	17
222	Transcriptional regulation of the liver beta-galactoside alpha 2,6-sialyltransferase by glucocorticoids.. <i>Journal of Biological Chemistry</i> , 1990, 265, 17849-17853.	3.4	63
223	Retinoic acid inhibits calmodulin binding to human erythrocyte membranes and reduces membrane Ca ²⁺ (+)-adenosine triphosphatase activity.. <i>Journal of Clinical Investigation</i> , 1990, 85, 1999-2003.	8.2	8
224	Transcriptional regulation of the liver beta-galactoside alpha 2,6-sialyltransferase by glucocorticoids. <i>Journal of Biological Chemistry</i> , 1990, 265, 17849-53.	3.4	51
225	Presence of Antibodies in the Sera of Patients with Graves' Disease Recognizing a 23 Kilodalton Fibroblast Protein*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1989, 69, 622-628.	3.6	76
226	Hormonal Regulation of Hyaluronate Synthesis in Cultured Human Fibroblasts: Evidence for Differences between Retroocular and Dermal Fibroblasts. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1989, 69, 1019-1023.	3.6	110
227	Retinoic acid blockade of imidazole-induced tyrosinase expression in B16 melanoma cultures: Similar effects of the active retinoid and triiodothyronine. <i>Biochemical and Biophysical Research Communications</i> , 1989, 162, 288-293.	2.1	7
228	Connective Tissue, Glycosaminoglycans, and Diseases the Thyroid*. <i>Endocrine Reviews</i> , 1989, 10, 366-391.	20.1	294
229	Retinoic Acid Is a Modulator of Thyroid Hormone Activation of Ca ²⁺ -ATPase in the Human Erythrocyte Membrane. <i>Journal of Biological Chemistry</i> , 1989, 264, 687-689.	3.4	33
230	Retinoic acid is a modulator of thyroid hormone activation of Ca ²⁺ -ATPase in the human erythrocyte membrane. <i>Journal of Biological Chemistry</i> , 1989, 264, 687-9.	3.4	25
231	Inhibition of imidazole-induced tyrosinase activity by estradiol and estriol in cultured B 16/C3 melanoma cells. <i>Journal of Cellular Physiology</i> , 1988, 134, 497-502.	4.1	6
232	The effect of regression towards the mean on visual disability rating scales. <i>Documenta Ophthalmologica</i> , 1988, 70, 331-337.	2.2	1
233	N-butyrate increases c-erb A oncogene expression in human colon fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 1988, 150, 259-262.	2.1	4
234	Glucocorticoid regulation of glycosaminoglycan synthesis in cultured human skin fibroblasts: Evidence for a receptor-mediated mechanism involving effects on specific de novo protein synthesis. <i>Metabolism: Clinical and Experimental</i> , 1988, 37, 179-184.	3.4	35

#	ARTICLE	IF	CITATIONS
235	3,3â€²,5-L-triiodothyronine but not L-thyroxine can block the induction of tyrosinase by imidazole in cultured B16 melanoma cells. Biochemical and Biophysical Research Communications, 1988, 155, 1293-1296.	2.1	2
236	Thyroid Hormone Regulation of Heme Synthesis in Rat Liver*. Endocrinology, 1988, 122, 1964-1967.	2.8	10
237	Multi-hormonal regulation of tyrosinase expression in B16/C3 melanoma cells in culture. Progress in Clinical and Biological Research, 1988, 262, 241-55.	0.2	2
238	Effect of testosterone on imidazole-induced tyrosinase expression in B16 melanoma cell culture. Cancer Research, 1988, 48, 3586-90.	0.9	7
239	Thyroid and Glucocorticoid Hormone Regulation of specific Protein Abundance in Cultured Human Skin Fibroblasts. Endocrine Research, 1987, 13, 61-67.	1.2	3
240	n-Butyrate inhibition of hyaluronate synthesis in cultured human fibroblasts.. Journal of Clinical Investigation, 1987, 79, 1493-1497.	8.2	31
241	Triiodothyronine Repression of Imidazole-Induced Tyrosinase Expression in B16 Melanoma Cells*. Endocrinology, 1986, 119, 2118-2123.	2.8	7
242	Glucocorticoid Regulation of Glycosaminoglycan Accumulation in Murine Fibroblasts. Endocrine Research, 1985, 11, 171-179.	1.2	0
243	Dexamethasone regulation of glycosaminoglycan synthesis in cultured human skin fibroblasts. Similar effects of glucocorticoid and thyroid hormones.. Journal of Clinical Investigation, 1984, 74, 2157-2163.	8.2	98
244	The consequences of inappropriate treatment because of failure to recognize the syndrome of pituitary and peripheral tissue resistance to thyroid hormone. Metabolism: Clinical and Experimental, 1983, 32, 822-834.	3.4	55
245	Thyroid hormone regulation of heme oxidation in the liver.. Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 7537-7541.	7.1	18
246	Nuclear Binding of [¹²⁵ I]Triiodothyronine in Dispersed Cultured Skin Fibroblasts from Patients with Resistance to Thyroid Hormone*. Journal of Clinical Endocrinology and Metabolism, 1982, 55, 502-510.	3.6	39
247	Regulation of Glycosaminoglycan Synthesis by Thyroid Hormone in Vitro. Journal of Clinical Investigation, 1982, 70, 1066-1073.	8.2	108
248	THE EFFECT OF THYROID HORMONE ON GLYCOSAMINOGLYCAN ACCUMULATION IN HUMAN SKIN FIBROBLASTS. Endocrinology, 1981, 108, 2397-2399.	2.8	33
249	Glucocorticoids enhance glucose uptake and affect differentiation and beta-adrenergic responsiveness in muscle cell cultures. Cell Differentiation, 1981, 10, 101-107.	0.4	8
250	Ultrastructural features of osmotic shock in mussel gill cilia. Journal of Ultrastructure Research, 1977, 60, 34-43.	1.1	6
251	Letter to the editor regarding Bartalena et al. 2022. Journal of Endocrinological Investigation, 0, , .	3.3	1